Currently, a phase II trial is underway to evaluate the therapeutic efficacy of 177Lu-TLX591, a radiolabeled PSMA-targeting antibody, in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent, oligometastatic, PSMA-expressing prostate cancer. Here, FOLH1 is linked to prostate carcinoma.